

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group Art Unit : Not Yet Assigned
Applicants : Guy W. Bemis, et al.
Application No. : Not Yet Assigned
Filed : Concurrently Herewith
For : INHIBITORS OF INTERLEUKIN-1 β CONVERTING ENZYME

New York, New York
June 21, 2001

Hon. Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to the issuance of the first Office Action in the above-identified application,
kindly amend the application as follows:

IN THE CLAIMS

Please cancel claims 1-75, 77-101, 108-117, and 119-124.

Please amend claim 76 as follows:

EXPRESS MAIL
EK708045951US

Please amend claim 76 as follows:

76. A method for treating or preventing a disease selected from the group consisting of IL-1 mediated disease, autoimmune disease, inflammatory disease, neurodegenerative disease, and infectious disease in a patient comprising the step of administering to said patient a pharmaceutical composition according to claim 125.

Please add claims 125-127.

125. A pharmaceutical composition comprising a compound according to any one of claims 102-107 or 118 and a pharmaceutically acceptable carrier.

126. A method for promoting wound healing in a patient comprising the step of administering to said patient a pharmaceutical composition according to claim 125.

127. A method for treating or preventing a disease selected from septic shock, septicemia, adult respiratory distress syndrome, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, insulin-dependent diabetes mellitus, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, or primary lateral sclerosis in a patient comprising the step of administering to said patient a pharmaceutical composition according to claim 125.

128. The method according to claim 127 wherein the disease is septic shock or rheumatoid arthritis.

[illegible]

Applicants have accordingly deleted claims 71-75 directed to pharmaceutical compositions having specific intended uses. Support for added claim 125 may be found throughout the specification as originally filed (see particularly, page 113, lines 17-21) and in claims 71-75 as originally filed.

Applicants request consideration of the application and early allowance of the pending claims.

may

Lisa A. Dixon (Reg. No. 40,995)

c/o FISH & NEAVE

New York, New York 10020

Tel.: (212) 596-9000

Fax.: (212) 596-9090

AMENDED CLAIMS MARKED TO SHOW AMENDMENTS

76. A method for treating or preventing a disease selected from the group consisting of IL-1 mediated disease, autoimmune disease, inflammatory disease, [and] neurodegenerative disease, and infectious disease in a patient comprising the step of administering to said patient a pharmaceutical composition according to [any one of claims 71-75] claim 125.